<DOC>
	<DOC>NCT01682473</DOC>
	<brief_summary>To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.</brief_summary>
	<brief_title>A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description>Open-label, uncontrolled, serial cohort, dose-escalation study evaluating two different dosing regimens (Arm 1: cycles of 5 days on drug and 2 days off drug), Arm 2: cycles of 21 days on drug and 7 days off drug).</detailed_description>
	<criteria>Japanese males or females &gt;= 20 years old Advanced (metastatic or unresectable) solid tumor ECOG performance status score of 0 or 1 and expected survival &gt;12 weeks Recovered from hematological toxicities of prior cancer therapies Previous treatment with PI3K inhibitor Serious/significant illnesses or underlying conditions, including diabetes or hepatic renal or CV disease. Other investigational agent within previous 4 weeks Participating in another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>PI3K inhibitor</keyword>
	<keyword>clinical trial</keyword>
</DOC>